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UMBILICAL CORD BLOOD STEM CELLS:
MY BODY MAKES THEM, BUT DO I GET TO
KEEP THEM? ANALYSIS OF THE FDA
PROPOSED REGULATIONS AND THE IMPACT
ON INDIVIDUAL CONSTITUTIONAL
PROPERTY RIGHTS
I. FDA PROMULGATION OF REGULATIONS REGARDING CORD BLOOD
STEM CELL BANKING
The Food and Drug Administration ("FDA") recently released a draft
document' regarding the proposed regulation of the collection of umbili-
cal cord blood stem cell2 products.3 The structure of the proposed regula-
tion was such that-it was likely to prove to be an obstacle to parents of
children dying of certain blood related illnesses.4 After much public con-
cern and discussion, the FDA proposed a new regulatory framework5 that
included regulatory oversight of cord blood stem cells at a regulatory
level much less onerous for the industry, technology, and parents of chil-
l. FOOD AND DRUG ADMINISTRATION, DRAFT DOCUMENT CONCERNING THE REGU-
LATION OF PLACENTAL/UMBILICAL CORD BLOOD STEM CELL PRODUCTS INTENDED FOR
TRANSPLANTATION OR FURTHER MANUFACTURE INTO INJECTABLE PRODUCTS, [Dkt. No.
96N-0002], (Dec. 1995) [hereinafter CORD BLOOD DRAFT DOCUMENT].
2. Cord blood stem cells are the blood that remains in the umbilical cord and the
placenta after birth. This blood was formerly discarded as waste. Today, however, the
cord blood stem cells may be retrieved through a simple procedure that may be performed
quickly by hospital personnel. Cord Blood Collection Information (visited Oct. 27, 1996)
<http://www.cordblood.com/collect.html>.
3. The draft document defines "cord blood stem cell products" as "products contain-
ing hematopoietic progenitor cells derived from placental/umbilical cord blood to be ad-
ministered to humans and applicable to the prevention, treatment, cure, diagnosis, or
mitigatio:1 of disease or injuries." CORD BLOOD DRAFT DOCUMENT, supra note 1, at 14.
4. Cord blood stem cell transplants may be useful in the treatment of diseases such as
leukemia, AIDS, and certain autoimmune diseases including diabetes and rheumatoid ar-
thritis, and is being investigated for use in the treatment of adenine deaminase deficiency.
Clare Thompson, Umbilical Cords: Turning Garbage into Gold, 268 SCIENCE 805, 805-06
(1995). Cord blood stem cell transplants have also been used to treat adrenoleukodys-
trophy, the disease of the young boy in the movie Lorenzo's Oil. Lilla Ross, Our First
Christma; Present, FLA. TIMES-UNION, Dec. 24, 1996, at Al.
5. FOOD AND DRUG ADMINISTRATION, PROPOSED APPROACH TO REGULATION OF
CELLULAR AND TISSUE-BASED PRODUCTS, [Dkt. No. 97N-0068], (Feb. 28, 1997) [hereinaf-
ter CELLULAR TISSUE FRAMEWORK].
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dren. Nevertheless, the proposed cord blood regulation gave rise to great
concern over whether it threatened the viability of the technology of cord
blood stem cell collection and transplantation and infringed upon the
rights of infants and their parents.'
Cord blood stem cell transplants were spotlighted in the media recently
when the daughter of baseball hall-of-famer, Rod Carew, received a cord
blood stem cell transplant 7 as treatment for her fatal leukemia8 after at-
tempts to find an appropriate bone marrow donor proved to be unsuc-
cessful.9 Research regarding the use of allogeneic1° cord blood stem cells
has been increasing. However, the majority of parents who are choosing
to bank their babies' blood do so as biological insurance for their children
rather than for general use, in hopes that they can provide their children
with the gift of life should they ever need it.l" The proposed cord blood
regulations threatened to infringe upon a parent's right to make choices
regarding their child's future. The proposed cord blood regulations also
impact the child's property right to reclaim their stored cord blood for
later use. In addition to foreclosing access to blood that has already been
banked, the proposed cord blood regulation would have denied the child
the right to bank its blood for later use. However, the proposed cord
blood regulations were perceived as a necessary action in response to the
advertising and banking of cord blood stem cells by various business
entities.12
6. See generally, Comments submitted to the Food and Drug Administration, [Dkt.
No. 96N-0002].
7. A Rare Umbilical-Cord Infusion Gives Carew's Daughter Chance, NEWSDAY Mar.
23, 1996, at 25.
8. Michelle Carew died from complications related to her leukemia within a month of
the transplant. It is unknown whether the transplant came too late for Michelle, or
whether cord blood transplants are ineffective in adults. Brian Alexander, Life's Blood,
SELF, Aug. 1996, at 125, 127.
9. The likelihood of finding an unrelated donor is thirty to forty percent for Cauca-
sians and decreases significantly for minorities, and the process of finding a donor may
take anywhere from three to six months. In the event that an unrelated donor can be
found, there is still a forty-five to ninety percent chance of the recipient developing graft-
versus-host-disease. David T. Harris, Experience in Autologous and Allogeneic Cord
Blood Banking, 5 J. HEMATOTHERAPY 123, 124 (1996).
10. "Allogeneic" refers to "molecules or cell types within a species that have identical
functions but are antigenically distinct." CONCEPTs IN IMMUNOLOGY AND IMMUNOTHER-
APEUTICS 503 (Jim Koeller, M.S. & Joseph A. Tami, Pharm. D. eds., 2d ed. 1992).
11. See Parents' Comments Submitted to the Food and Drug Administration, [Dkt.
No. 96N-0002] (on file with the author).
12. Entities such as CorCell, Cord Blood Registry, ViaCord, and the New York Blood
Center have been banking cord blood stem cells for parents of newborns consistent with
industry standards set by the International Society for Hematotherapy & and Graft Engi-
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This Comment examines the law leading up to the proposed cord blood
regulations on umbilical/placental cord blood stem cells, and analyzes the
impact of the proposed regulations on the infant, by examining the status
of cord blood stem cells as a property interest. Next, this Comment con-
siders -whether the regulations would have acted as a deprivation of prop-
erty without Due Process had they not been replaced by the Cell Tissue
Framework. This Comment then reviews the Proposed Approach to
Regulation of Cellular and Tissue-Based Products, and the appropriate-
ness of the reconsideration of the Cord Blood Draft Document. Finally,
this Comment concludes that the regulations would have deprived infants
of the right to property without adequate Due Process, the regulations
were more burdensome than necessary to effectuate the government in-
terest, and that the Cellular Tissue Regulations are an appropriate frame-
work under which cord blood stem cells should be regulated.
II. FDA DRAFT DOCUMENT CONCERNING THE REGULATION OF
PLACENTAL/UMBILICAL CORD BLOOD STEM
CELL PRODUCTS
The proposed cord blood regulations 13 stated that the FDA had deter-
mined: (1) that it was appropriate to regulate placental/umbilical cord
blood stem cell products as biologics as set forth in the Public Health
Services Act; 4 and (2) that cord blood stem cells fell within the definition
of drugs and were subject to the regulations applicable to drugs15 within
the Federal Food, Drug, and Cosmetic Act ("FDCA"). 16 The proposed
regulations were very burdensome. First, the FDA's proposed cord blood
regulations were far more restrictive than those required for blood prod-
ucts, even though blood product regulations would appear to have been
the likely regulatory mechanism to use for cord blood stem cell prod-
ucts.17 Second, regulating cord blood stem cells as biologics renders them
neering ("ISHAGE"). FOUNDATION FOR THE ACCREDITATION OF HEMATOPOIETIC CELL
THERAFY ("FAHCT"), STANDARDS FOR HEMATOPOIETIC PROGENITOR CELL COLLEC-
TION, PROCESSING AND TRANSPLANTATION (May 1996).
13. See generally CORD BLOOD DRAFT DOCUMENT, supra note 1.
14. 42 U.S.C. §§ 262-263 (1994).
15. CORD BLOOD DRAFT DOCUMENT, supra note 1, at 4.
16. 21 U.S.C. §§ 310.100-310.546 (1996).
17. Additional Standards for Human Blood and Blood Products, 21 C.F.R. §§ 640.1-
640.120 (1996). Blood collection and storage is subject to extensive regulation. The major-
ity of regulations were imposed after the disaster in the 1980's in which blood untested for
HIV had to be discarded. See 21 C.F.R. §§ 640.5(f), 610.45 (1996). Blood products are
not, however, subject to an investigational new drug application ("IND") unless they have
been extensively manipulated. FOOD AND DRUG ADMINISTRATION, DRAFT DOCUMENT
19981
480 Journal of Contemporary Health Law and Policy [Vol. 14:477
subject to FDA procedures for both establishment licensure18 and prod-
uct licensure19 in order to ensure their safety, purity, and potency. 0
Third, cord blood stem cells that are intended for transplant into humans
are further subject to the investigational new drug application ("IND")2 1
requirements during both the clinical development and licensure as final
products.22 Finally, cord blood stem cells intended for use as source ma-
terial for further manufacture were also to be subject to licensure, unless
they could be covered previously under the licensure of the final
product.2 3
The proposed cord blood regulations indicated that cord blood stem
cells were to be subject to an IND, a process normally utilized for the
approval of drugs.24 An IND must be submitted to the FDA when an
investigator intends to conduct clinical investigations on an investiga-
tional new drug.2 5 Although the IND mechanism has not been utilized in
relation to transplants,2 6 it has been required on clinical trials of gene
therapy and trials of living autologous cells manipulated ex vivo that are
intended for structural repair and reconstruction.2 ' The IND process is
CONCERNING THE REGULATION OF PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL
PRODUCTS INTENDED FOR TRANSPLANTATION OR FURTHER MANUFACTURE INTO INJECT-
ABLE PRODUCTS, (Feb. 1996). The FDA considers manipulated blood products to be bio-
logics subject to establishment licensure, product licensure, and INDs. Id.
18. Establishment Licenses, 21 C.F.R. §§ 601.1-601.10 (1996). An establishment li-
cense is issued "only after inspection of the establishment and upon a determination that
the establishment complies with the applicable standards prescribed in the regulations in
this subchapter." 21 C.F.R. § 601.10(a).
19. Product Licenses, 21 C.F.R. §§ 601.20 (1996). The manufacturer must submit an
application that includes "data derived from nonclinical laboratory and clinical studies
which demonstrate that the manufactured product meets prescribed standards of safety,
purity, and potency." 21 C.F.R. § 601.2(a).
20. CORD BLOOD DRAFT DOCUMENT, supra note 1, at 3, 10.
21. The Code defines an "Investigational New Drug" as: "a new drug, antibiotic drug,
or biological drug that is used in a clinical investigation." The term also includes a "biolog-
ical product that is used in vitro for diagnostic purposes." Investigational New Drug Appli-
cation, 21 C.F.R. § 312.3(b) (1996).
22. CORD BLOOD DRAFT DOCUMENT, supra note 1, at 5.
23. Id. at 10-11.
24. Investigational New Drug Application, 21 C.F.R. § 312 (1996).
25. See supra note 21 and accompanying text.
26. FDA has required several investigators to submit an IND in order to perform xe-
notransplants. In addition, the FDA has promulgated guidelines that require an IND for
any investigator who intends to conduct xenotransplants. The FDA also intends to develop
guidelines outlining the necessary requirements of an IND seeking approval of a xeno-
transplant request. DRAFT PUBLIC HEALTH SERVICE ("PHS") GUIDELINE ON INFECTIOUS
DISEASE ISSUES IN XENOTRANSPLANTATION, 61 Fed. Reg. 49,920 (1996).
27. DEPARTMENT OF HEALTH AND HUMAN SERVICES, TRANSCRIPT OF PUBLIC HEAR-
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properly used for biologics, which are considered, based upon their use,
to be within the purview of drug regulations.28 The IND process has not,
however, been extended to blood products, particularly those which have
not been manipulated.29 It was thus inappropriate to extend the IND
process to cover cord blood stem cell products.
The purpose of the FDA's proposed cord blood regulations was to en-
sure that blood cells do not contain transmissible agents, are not dam-
aged, and that appropriate records are maintained.3 ° None of the
proposed cord blood regulations require, however, that the blood estab-
lishments show therapeutic effectiveness.3 ' The FDA has issued Draft
Guidance in which it proposes to regulate peripheral blood stem cells,
which are isolated from the circulating blood of the donor, with the same
scheme utilized for blood products.32
ING ON PRODUCTS COMPRISED OF LIVING AUTOLOGOUS CELLS MANIPULATED Ex Vivo
AND INTENDED FOR STRUCTURAL REPAIR AND RECONSTRUCTION (Nov. 16-17, 1995).
28. Essentially the IND regulations require that an investigator submit an application
and then wait thirty days before performing any clinical studies. Investigational New Drug
Application, 21 C.F.R. § 312 (1996). In addition to the application, the investigator must
make asurances that he will refrain from performing clinical studies or restrict those stud-
ies at the request of the FDA. Investigational New Drug Application, 21 C.F.R.
§§ 312.23(a), 312.40 (1996). Prior to participating in an investigation, the investigator must
provide 1he sponsor with a completed Form FDA-1572, a curriculum vitae, and the clinical
protocol. 21 C.F.R. § 312.53 (1996). Neither the sponsor nor the investigator is permitted
to make a profit on an investigational drug until it has been granted final drug approval
unless: "there is adequate enrollment in ongoing clinical investigations, (2) the price
charged is limited to a 'cost recovery' level, (3) the drug is not commercially promoted or
advertised, and (4) the sponsor of the drug is actively pursuing marketing approval."
Kleinfeld et al., Human Drug Regulations: Comprehensiveness Breeds Complexity, in FOOD
AND DRUG LAW 243, 282 (Richard M. Cooper ed., 1991).
29. See FOOD AND DRUG ADMINISTRATION, DRAFT DOCUMENT CONCERNING THE
REGULATION OF PERIPHERAL BLOOD HEMATOPOIETIC STEM CELL PRODUCTS INTENDED
FOR TRANSPLANTATION OR FURTHER MANUFACTURE INTO INJECTABLE PRODUCTS (Feb.
1996).
30. Joint Comments of Coriell Institutes For Medical Research and Corcell, Inc. sub-
mitted to the Food and Drug Administration, [Dkt. No. 96N-0002] (July 26, 1996) [herein-
after Joint Comments].
31. Id.
32. The Draft Document was distributed at Peripheral Blood Stem Cell Workshop,
Transcript, Feb. 22-23, 1996; the workshop was announced in PERIPHERAL BLOOD STEM
CELLS: DISCUSSION OF PROCEDURES FOR COLLECTION, PROCESSING, AND PRODUCT
CHARACTERIZATION; NOTICE OF PUBLIC WORKSHOP, 61 Fed. Reg. 4786 (Feb. 8, 1996).
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III. FOOD AND DRUG ADMINISTRATION: HISTORY LEADING UP TO
THE REGULATIONS
The Public Health Service was created by an act of Congress 33 and is
the independent agency from which the FDA derives its authority.34 In
1927, the Federal Food and Drug Administration was created 35 to protect
the public from unscrupulous manufacturers of medicines that were prey-
ing on the innocent in their quest for financial gain, and to give the FDA
regulatory authority over foods, drugs, devices, and cosmetics. 36
Throughout the evolution of the agency, the FDA was eventually granted
authority over foods,3 7 drugs,38 devices, 39 biological products,40 and
cosmetics. 4'
The Biologics Act 42 was passed in 1902 in response to the deaths of
more than ten school children following their vaccination with contami-
nated diptheria antitoxin.43 Initially, the Biologics Act was only intended
33. Public Health Services Act, 42 U.S.C. §§ 201-300 (1994).
34. Federal Food, Drug, and Cosmetic Act ("FDCA"), 21 U.S.C. § 393 (1994).
35. Id.
36. See Milestones in U.S. Food and Drug Law History (visited Nov. 3, 1996), <http://
www.fed.gov/opacom/backgrounders/miles.html>.
37. 21 U.S.C. §§ 312-350b (1994). Foods include "(1) articles used for food or drink
for man or other animals, (2) chewing gum, and (3) articles used for components of any
such article." Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321(f) (1994).
38. 21 U.S.C. §§ 351-360b (1996). Drugs include:
(A) articles recognized in the official United States Pharmacopoeia, official Ho-
meopathic Pharmacopoeia of the United States, or official National Formulary, or
any supplement to any of them; and (B) articles intended for use in the diagnosis,
cure, mitigation, treatment, or prevention of disease in man or other animals; and
(C) articles (other than food) intended to affect the structure or any function of
the body of man or other animals; and (D) articles intended for use as a compo-
nent of any article specified in clauses (A), (B), or (C) of this paragraph.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321(g)(1).
39. 21 U.S.C. §§ 351-353, 360 (1994). Devices include "instrument[s], apparatus....
and contrivance[s], including any component[s], part[s], or accessory, which is , - . . . (2)
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in
man or other animals, or (3) intended to affect the structure or any function of the body of
man or other animals." Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321(h).
40. 42 U.S.C. §§ 262-263 (1994). Biological products include "any virus, therapeutic
serum, toxin, antitoxin, vaccine, blood, blood component, or derivative, allergenic product,
or analogous product or arsphenamine or its derivative (or any other trivalent organic
arsenic compound), applicable to the prevention, treatment, or cure of diseases or injuries
of man." Public Health Service Act, 42 U.S.C. § 262(a) (1996).
41. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 361-363 (1994).
42. Biologics Act, 42 Public Health Service Act § 351, 42 U.S.C. § 262 (1996).
43. William R. Pendergast, Biologic Drugs, in FOOD AND DRUG LAW 306-308 (Rich-
ard M. Cooper ed. 1991).
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to cover vaccines.' Congress specifically amended the Act in 1970 to
include blood and blood components or derivatives.45 Following the
transfer to the FDA of the authority to enforce the Biologics Act in 1972,
the FDA applied several provisions of the FDCA to blood products.46
The impetus for the FDA's decision to regulate cord blood stem cells
was the numerous inquiries from physicians and parents, resulting from
assertions made by the industry while soliciting parents to bank their ba-
bies' cord blood.47 Companies were promising parents the world, the
stars, and the hope that they could provide the one thing that one day
might save their baby's life - a transplant. The cord blood banking ser-
vice was offered to parents with family histories of blood diseases and
cancers., those with a child suffering from a life threatening illness, as well
as those. whose children had very little risk of ever falling victim to a life
threatening disease treatable with a cord blood transplant.48 In addition,
there was a great deal of concern within the industry that premature com-
mercialization could stunt the potential growth of the technology before
it had an opportunity to generate adequate research on the safety and
efficacy of the procedure.49 In sum, the FDA was particularly concerned
with what it referred to as the "vigorous commercial activity" in cord
blood stem cell banking.5
0
IV. BACKGROUND OF UMBILICAL CORD BLOOD STEM
CELL TRANSPLANTS
A. Scientific Theory Behind the Procedure
1. Possible Superiority Over Bone Marrow Transplants
Umbilical cord blood stem cells5' have always been disposed of with
44. Id.
45. Public Health Service Act, 42 U.S.C. § 300ff-72 (1996). See also Current Good
Manufacturing Practices for Blood and Blood Components, 21 C.F.R. § 606 (1996); Estab-
lishment Registration and Product Licensing for Manufacturers of Human Blood and
Blood Products, 21 C.F.R. § 607 (1996). See also PETER BARTON Hurr & RICHARD A.
MERRILL, FOOD AND DRUG LAW 678 (2d ed. 1991).
46. See id. at 681.
47. Susan Cohen, Whose Blood Is It Anyway?, WASH. POST MAG., Aug. 18, 1996, at
11, 15.
48. See Cord Blood Registry (visited Oct. 27, 1996) <http://www.cordblood.com>.
49. Cohen, supra note 47, at 27.
50. 1d. at 29.
51. Hal E. Broxmeyer et al., Human Umbilical Cord Blood as a Potential Source of
Transplantable Hematopoietic Stem/Progenitor Cells, 86 PROC. NAT'L. ACAD. Sci. U.S.A.
3828 (190).
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the rest of the waste material after birth. However, due to advances in
medicine the life-giving potential of the cord blood has recently been dis-
covered. The umbilical cord blood is rich with pluripotent 52 stem cells
that are capable of proliferating into the various blood components that
comprise whole blood.53 It is the proliferative potential of the pluri-
potent stem cells that make them viable substitutes for a traditional bone
marrow transplant.54 Cord blood stem cells possess other advantages
over the typical bone marrow transplant.55 They can be harvested after
birth, thereby avoiding the invasive procedure harvesting bone marrow
from a donor requires. 56 Additionally, the likelihood that the cord blood
stem cells will carry infectious agents57 is lower than bone marrow from
an adult donor since the source is a new infant who is less likely to have
been exposed to various sensitizers or allergens.58 Finally, the immature
state of the stem cells indicates that the recipient is less likely to be sensi-
tive to slight HLA59 mismatches, and as a result, use of the stem cells may
decrease the risk of graft-versus-host disease.6°
52. Each pluripotent stem cell is capable of not only dividing into two identical cells,
but it may also develop into the different types of cells that make up blood until all the
necessary components are represented. Elise Hancock, Stalking the Stem Cell, JOHNS HoP-
KINS MAG., June 1996, at 37, 39.
53. Whole blood is comprised of erythrocytes, granulocytes, monocytes, megakaryo-
cytes, platelets, T-lymphocytes, B-lymphocytes, and plasma. ARTHUR C. GUYTEN, M.D.,
TEXTBOOK OF MEDICAL PHYSIOLOGY 357 (8th ed. 1991).
54. Bone marrow also contains cells capable of proliferating into whole blood, how-
ever, the stem cells in bone marrow are much more mature than those in the umbilical cord
and require a closer match than that which is necessary for cord blood. Richard Saltus,
Umbilical Cord Cells Eyed for Transplants, BOSTON GLOBE, July 18, 1996, at A3.
55. Stem Cell Transplants Soon May Render Marrow Transplants Obsolete, F-D-C RE-
PORTS ("THE PINK SHEET"), Mar. 13, 1995.
56. Bone marrow donors must undergo anesthesia and painful surgery in order to har-
vest their marrow. Blood From Placenta Can Aid Leukemia Patients, N.Y. TIMES, July 18,
1996, at A19.
57. Cord blood transplants are rarely infected with viruses such as cytomegalovirus
(CMV) or Epstein-Barr virus ("EBV") which may cause problems for a transplant recipi-
ent. Cord Blood Transplants (visited Oct. 29, 1996) <http://cancer.med.upenn.edu/spe-
cialty/chemo/bmt/newsletter/N33/cord.html>.
58. A sensitizer is "a substance that causes dermatitis only after alteration (sensitiza-
tion) of the skin by previous exposure to that substance." STEDMAN'S MEDICAL DICTION-
ARY 1597 (26th ed. 1995).
59. HLA antigens are located on the surfaces of all cells. There are nearly 150 differ-
ent antigens which are coded for by only 6 genes. It is nearly impossible for two people to
have the exact same six HLA antigens and any variation may be responsible for rejection.
GUYTEN, supra note 53, at 389.
60. Joan Stephenson, Ph.D., Terms of Engraftment: Umbilical Cord Blood Transplants
Arouse Enthusiasm, 273 JAMA 1813, 1814 (1995).
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The benefits of cord blood transplants61 over traditional bone marrow
transplants62 seem overwhelming. However, there are limitations to the
effectiveness of the procedure. Whether cord blood transplants will be
successful in adults is debatable. Specifically, one may question whether
the cord blood contains sufficient stem cells to repopulate an adult body
adequately.63 The majority of recipients thus far have been under 70
kilograms (156 pounds) and have shown promising success. 64 There also
have been reports of successful cord blood transplants in patients weigh-
ing up to 81 kilograms (178 pounds), contradicting the apparent correla-
tion between the effectiveness of the transplant and the patient's
weight.65
Graft-versus-host disease66 is a life-threatening complication possible
in all transplants, but the lower incidence in a cord blood transplant may
not necessarily be as favorable as one might believe. For example, leuke-
mia patients appear to benefit from a slight graft-versus-leukemia ef-
fect,6 7 which helps to eradicate the patient's system of any remaining
cancerous cells.68 To eliminate this effect entirely may prove detrimental
to the overall therapy.
69
61. [he procedure for both cord blood stem cell transplants and bone marrow trans-
plants are largely the same. Essentially, the patient has her bone marrow and cancerous
cells eliminated using chemotherapy or radiation and then the stem cells or bone marrow
progenitor cells are infused into the patient to give rise to the patient's blood production
system and immune system. Stephenson, supra note 60, at 1814.
62. Bone marrow transplant procedures involve irradiating the patient's existing bone
marrow and then infusing the patient with the donated marrow. Following the initial pro-
cedure the patient must undergo extensive anti-rejection therapy which suppresses the im-
mune sy:;tem. Although the ultimate transplants procedures are very similar, the bone
marrow transplant requires a harvest from a matched donor. Assuming that a suitable
donor has been located, the bone marrow recovery process is a painful, invasive procedure
that often involves general anesthesia. The International Cord Blood Foundation (visited
Oct. 29, 1996) <http://www.infinityweb.com/cordblood/faq.html>.
63. Jean-Philippe Laporte et al., Cord-Blood Transplantation From and Unrelated Do-
nor in an Adult with Chronic Myelogenous Leukemia, 335 NEw ENG. J. MED. 167 (1996).
64. Cord Blood Transplants, supra note 57
65. The International Cord Blood Foundation ("ICBF") (visited Oct. 29, 1996) <http://
www.con/cordblood/brochure.html>.
66. Graft-versus-host-disease is "a pathological reaction that is caused by the trans-
plantatioa of competent T cell into an incompetent host, that is, one unable to reject them.
This reaction occurs when the donor cells attack the host." CONCEPTS IN IMMUNOLOGY
AND IMMUNOTHERAPEUTICS, supra note 10, at 509.
67. Graft-versus-leukemia effect is "the decreased incidence of leukemia relapses seen
in patients receiving allogeneic transplants in comparison with autologous transplants."
Id.
68. See Cohen, supra note 47, at 15.
69. See id.
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2. The Difference Between Allogeneic and Autologous Transplants
The distinction between autologous7 ° and allogeneic71 transplants is
that autologous transplants are banked for use by the donor, and the do-
nor does not intend to permit the sample to be used in the general popu-
lation but rather only for himself. The difficulties of finding an
appropriate donor match are not present in autologous transplants be-
cause of the elimination of the risks of graft-versus-host disease and rejec-
tion.7' Allogeneic samples are banked for use by the general population.
Therefore, the donor and the recipient are generally unknown to one an-
other; much like the banking of whole blood.73 Alternatively, the donor
may designate the person to receive the allogeneic transplant. It is possi-
ble to bank a sample for either autologous or allogeneic transplant, and it
is up to the donor - actually, the newborn donor's parents - to desig-
nate the purpose for which the sample will be used.
3. Preservation Procedures74
The preservation of cord blood is a simple, painless, and minimally in-
vasive procedure. The collection center selected by the expectant mother
to bank her baby's cord blood sends her a collection kit. She must bring
the collection kit with her to the delivery room.75 The physician is shown
a short five-minute instructional video on the retrieval process that is very
similar to a standard phlebotomy. 6 The umbilical cord is clamped after
delivery of the baby, and blood is withdrawn into syringes either while
the placenta is still in utero or after it has been delivered.77 At this time,
70. "Autologous" refers to a transplants where the donor and the recipient are the
same individual, for instance, skin grafts. STEDMAN'S MEDICAL DICrIONARY, supra note
58, at 170.
71. "Allogeneic" refers to a transplant within a species. STEDMAN'S MEDICAL DIc-
TIONARY, supra note 58, at 34.
72. Alexander, supra note 8, at 125-26.
73. Cohen, supra note 47, at 26. The New York Blood Center has been banking cord
blood stem cells for autologous use as a participant in a National Heart, Lung and Blood
Institute pilot study. Id.
74. See generally Robert A. Dracker, Cord Blood Stem Cell: How to Get Them and
What to Do with Them, 5 J. HEMATOTHERAPY 145 (1996).
75. Cord Blood Collection Information, supra note 2. The Cord Blood Registry kit
contains: three 60 cc pre-heparinized syringes, three 18 gauge needles, two plastic bags, and
insulated packaging for shipping with labels. Id.
76. COLLECTION PROCEDURES FOR UMBILICAL CORD BLOOD STEM CELL SAMPLES
(Cord Blood Registry 1995); Umbilical Cord Blood for Bone Marrow Transplantation, 38
MED. LETrER 2 (Aug. 16, 1996).
77. Caesarean deliveries will also produce bankable cord blood samples. Cord Blood
Collection Information, supra note 2.
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aliquots are taken for testing, HLA-typing, cell counts, and other future
testing..78 An anticoagulant and a cryopreservative are added to the cord
blood s;ample, and then the cord blood is stored under liquid nitrogen.79
The cord blood must then be received by the collection center8" within
twenty-two hours.8' An average collection is 75 to 80 cubic centimeters
("cc"), but any volume between 40 cc to 200 cc will be sufficient for
banking.82
4. Potential Treatment for Many Life-threatening Diseases
Cord blood transplants present many possibilities for treating life-
threatening diseases.83 The nature of blood in the human circulatory sys-
tem makes therapies involving blood a promising treatment for blood dis-
eases. The first cord blood transplants84 were conducted while
researching treatments for Fanconi's anemia. 85 Today efforts have been
78. Umbilical Cord Blood for Bone Marrow Transplantation, supra note 76, at 2.
79. There is some disagreement as to the viability of tissues stored in deep freeze and
the length of time that those tissues will remain viable. A bank in Vancouver, British
Columbia indicates that cord blood may be held and remains transplantable for up to fif-
teen years, however, since the cells are held in suspended animation, in theory, they may
be pres.erved indefinitely. Lifebank Cryogenics (visited Oct. 29, 1996) <http://
www.lifebank.com/faq.html>.
80. The samples are mailed by overnight courier which creates the interstate nexus
required for FDA regulation.
81. The outside window for final processing is 48 hours, but a larger sample has been
processed up to 72 hours after collection. Cord Blood Collection Information, supra note
2.
82. Id.
83. See generally CORD BLOOD REGISTRY, UMBILICAL CORD BLOOD BANKING: A
NEW BInTH OPTION FOR YOUR FAMILY 2 (1997); David Brown, Umbilical Cord Blood
Found Useful In Fighting Disease, WASH. POST, July 13, 1996, at A3; Lucette Lagnado, Cell
Transpla'nts From Newborns Found Major Help in Fighting Blood Cancers, WALL ST. J.,
July 18, 1996, at B5.
84. The first successful transplant was performed in France in 1988 on a five year old
child wilh Fanconi's's Anemia. The patient's newborn sister was a perfect match, but was
too young to donate bone marrow. Given the gravity of the illness, researchers trans-
planted -ord blood stem cells preserved from the sister's umbilical cord and placenta, and
thereby the patient's bone marrow was restored. Eliane Gluckman, M.D. et al., Hemato-
poietic Reconstitution in a Patient with Fanconi's's Anemia by Means of Umbilical-Cord
Blood Fom an HLA-Identical Sibling, 321 NEW. ENG. J. MED. 1174 (1989). See also Cord
Blood )tem Cell Transplants (visited Oct. 29, 1996) <http://www.fhcrc.org/-pubrel/
CNes1996/Jan4/Cord.htm>; Cord Blood Transplants, supra note 57.
85. Fanconi anemia is an inherited anemia that leads to aplastic anemia and bone mar-
row failure. The disease often presents itself between the ages of 3 and 12 with extreme
fatigue and continual colds and viral infections. A recent study indicates that Fanconi ane-
mia patients develop leukemia or other cancers. Fanconi Anemia Fact Sheet (visited Oct.
28, 1996) <http://www2.cybernex.net/-jj/fa-facts.html>.
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made to utilize the advances in genetic research, coupled with cord blood
research, to treat such illnesses as adenine deaminase deficiency,86 thalas-
semia,87 sickle cell anemia, 88 and other genetically linked disorders.89
Researchers hope the genetic technology used to treat genetically linked
diseases may one day be effective in the treatment of AIDS.9°
B. Future of Research for Cord Blood Stem Cell Transplants
The research into cord blood transplants is forging ahead with each
success. Cord blood holds so much potential that the National Heart
Lung and Blood Institute ("NHLBI") has proposed funding,9' out of its
own budget, for a study into cord blood banking. 92 The study is projected
to proceed for five years,93 and will support two to four unrelated donor
banks, six to eight transplant centers, and one coordinating center.94 The
NHLBI hopes the study will establish the viability of cord blood trans-
plants as well as appropriate preservation procedures.95
The proposed cord blood regulations would have had a major impact
on the progress of the research by requiring the submission of an IND
application, a process which would itself restrict access to cord blood
stem cells that have been banked.96 Moreover, the requirements would
have acted as a roadblock to patients desperately needing the life-saving
therapy. The costs associated with the IND and the subsequent new drug
86. Adenine deaminase deficiency is a fatal genetic deficiency that is treated by in-
serting normal genes into the cord blood then transplanting them into the infant. Cohen,
supra note 47, at 29.
87. Surapol Issaragrisil, Cord Blood Transplantation in Thalassemia, 20 BLOOD CELLS
259 (1994). See also Gluckman, et al., supra note 84, at 1174.
88. "Sickle cell anemia" is a "chronic familial anemia in which a large proportion or
majority of the red cells in the blood are sickle cells and which occurs mainly in persons of
Negro blood." WEBSTER'S THIRD NEW INTERNATIONAL DICTIONARY 2111 (1986).
89. Stephenson, supra note 60, at 1813.
90. Researchers plan to insert an HIV-resistant gene into cord blood collected from a
baby born to an HIV infected mother. The baby will still be HIV positive, but will not
develop the signs and symptoms of AIDS. Angela Gonzales, Unbillical Blood Could Fight
HIV, Bus. J. - PHEONIX & VALLEY SUN, Mar. 19, 1995, at 29.
91. The amount allocated to the five-year study is 25 million dollars. Alexander, supra
note 8, at 159.
92. Cohen, supra note 47, at 29.
93. NHLBI Will Submit Stem Cell IND to FDA For Five Year Project to Study Cord
Blood Bank Viability, F-D-C REPORTS ("THE BLUE SHEET"), Dec. 20, 1995, at 5-6.
94. National Heart Lung and Blood Institute, Request for Proposals (July 1996).
95. NHLBI Will Submit Stem Cell IND to FDA For Five Year Project to Study Cord
Blood Bank Viability, supra note 93, at 5-6.
96. See generally Comments submitted to the Food and Drug Administration, [Dkt.
No. 96N-0002].
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application ("NDA")97 would have caused cord blood stem cell banking
fees to skyrocket above their already high levels because cord blood
banks would be required to conduct studies and submit the requisite
data.98 Because, investigational status would have been conferred upon
cord blood transplants patients would have limited access to the proce-
dure because health insurance companies would have used the investiga-
tional status to justify denying insurance benefits and most patients would
be unable to finance their own transplant.99 Patients would have had ac-
cess to the procedure within the proposed cord blood regulations, but
only through compliance with the rigorous requirements.
C. Public Response to the FDA Proposed Cord Blood Regulations
The FDA received an overwhelming response to the publication of the
proposed cord blood regulations in the form of comments submitted to
the docket.' The majority of the comments were submitted by con-
cerned parents and medical personnel expressing alarm and apprehen-
sion about the FDA's proposed mechanism to regulate cord blood stem
cell transplants in a manner similar to drugs through the IND process.'
The majority of the parents understood that the regulatory mechanism
parallels that of drugs; it meant that cord blood stem cell transplants were
doomed to suffer the same delays afflicting new drugs.10 2 A seven to
fourteen year wait, typical for new drug approval, is unacceptable to par-
ents whose children are dying of blood related diseases that could be
treated and potentially cured today through a cord blood transplant. Fur-
thermore, those parents who had already banked their baby's blood were
concerned that the FDA would deny them access to the blood when they
really needed it.' 0 3 That concern raises a constitutional question of par-
ents' rights to bank their babies' tissue, and ultimately, the rights to ac-
cess it at will. Additionally, the industry objected to the method by which
97. 21 C.F.R. pt. 314 (1997).
98. Se Comments of Cord Blood Registry, submitted to the Food and Drug Adminis-
tration, [Dkt. No. 96N-0002] (Jul. 26, 1996) [hereinafter Cord Blood Registry Comments].
99. See id.
100. FDA has received over 500 comments submitted to Docket No. 96N-0002. See
generally Comments submitted to the Food and Drug Administration, [Dkt. No. 96N-
0002].
101. See Cord Blood Registry Comments, supra note 98, at Attachment 1.
102. See generally Comments submitted to the Food and Drug Administration, [Dkt.
No. 96N-0002].
103. See generally id.
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the proposed cord blood regulations were promulgated.1 04 The proposed
cord blood regulations were promulgated without utilizing notice-and-
comment procedures required by the Administrative Procedure Act."°5
Moreover, the proposed cord blood regulations simply presumed interim
compliance with the regulations. 6
V. PROPOSED APPROACH TO REGULATION OF CELLULAR AND
TISSUE-BASED PRODUCTS
The FDA held a series of meetings to elucidate the technical issues
related to cord blood stem cell collection, preparation, processing, stor-
age, and characterization. 0 7 At the conclusion of these meetings, the
FDA acknowledged that the traditional regulatory scheme used for other
biologicals may not be appropriate for peripheral and cord blood hema-
topoietic stem/progenitor cells and other cellular and tissue-based prod-
ucts. Thus, the proposed cord blood regulations were inappropriate. The
FDA then released the Proposed Approach to Regulation of Cellular and
Tissue-Based Products ("Cellular Tissue Framework").10 8
The Cellular Tissue Framework creates a tiered approach to regulating
human cellular and tissue-based products - including cord blood stem
cells. The framework focuses on preventing the use of contaminated tis-
sues that carry the potential to transmit infectious diseases,'0 9 preventing
mishandling or improper processing that might result in contamination or
products that are of inadequate quality,"10 and ensuring that clinical
safety and efficacy are demonstrated for highly processed tissues, tissues
used for non-homologous uses, tissues combined with non-tissue compo-
nents, or have a systemic effect."' It was the FDA's intention to provide
the minimum federal regulatory requirements and increase the require-
ments commensurate with the potential risks.
104. See Cord Blood Registry Comments, supra note 98, and Joint Comments, supra
note 30.
105. Administrative Procedure Act, 5 U.S.C. § 553(b) (1996). See also Cord Blood
Registry Citizen's Petition for Stay of Administrative Action (June 6, 1996) [hereinafter
Citizen's Petition](on file with the author).
106. CORD BLOOD DRAFT DOCUMENT, supra note 1, at 1.
107. PUBLIC WORKSHOP, PROCEDURES FOR PREPARATION AND STORAGE OF CORD
BLOOD STEM/PROGENITOR CELLS FOR TRANSPLANTATION, 60 Fed. Reg. 58,088 (Nov. 24,
1995); PUBLIC WORKSHOP, PROCEDURES FOR THE PREPARATION OF HUMAN PERIPHERAL
BLOOD STEM/PROGENITOR CELLS, 61 Fed. Reg. 4,786 (Feb. 8, 1996).
108. CELLULAR TISSUE FRAMEWORK, supra note 5.
109. Id. at 6, 8.
110. Id. at 11.
111. Id. at 20.
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The FDA intends to phase in the requirements, beginning with registra-
tion arid listing, utilizing an electronic system in development by the
FDA. The Agency also intends to require communicable disease testing,
and to develop and promulgate processing standards. Following the de-
velopment of processing standards, the FDA then plans to issue licenses
based on the certification that is submitted with the registration and
listing.' 12
The Cellular Tissue Framework is a rational response to the valid con-
cerns of the industry and concerned citizens. A tiered approach, whereby
autologous stem cells are subject to minimal regulations and allogeneic
stem cells for non-family members are subject to greater regulatory con-
trol addresses the concerns of the FDA without ignoring the needs of
individuals.
A. Autologous Stem Cells and Allogeneic Stem Cells For Use In
Family Members
Submission of clinical safety and effectiveness data for cord blood stem
cells for allogeneic or related family use, provided the cells are minimally
manipulated and not combined with other non-tissue components is not
required. 113 Screening and testing of the donor and the banked stem cells
are to b- conducted prior to banking and release." 4 The FDA has deter-
mined that cells to be used from a family-related donor must be tested,
but that the family shall make the ultimate decision whether to utilize
contaminated cells. Cells to be banked and used later by the donor are
subject t:o less stringent requirements. The framework recommends that
cells to be used by family members undergo the same testing, however, it
does not make such testing a requirement. 1 5 Specifically, because cord
blood stem cells are rich in leukocytes they should be tested for human T-
cell lymphotropic virus ("HTLV"), and cytomegalovirus ("CMV").
Other testing should include HIV, HCV, HBV, and screening for those
who are: high risk for HIV and Hepatitis. While there will be no
premarket requirements concerning communicable disease testing in al-
logeneic circumstances, the FDA retains authority to inspect banking
facilities.
112. Id. at 26-27.
113. CELLULAR TISSUE FRAMEWORK, supra note 5, at 20-21.
114. Id. at 13.
115. Id. "[S]creening and testing procedures would be recommended rather than re-
quired for such autologous [use] . .. because 1) autologous use of cells ... raises lesser
communicable-disease concerns than does allogeneic use ..... Id.
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The Cellular Tissue Framework considers cord blood stem cells to be a
homologous use and in some instances, possessing a metabolic func-
tion. 16 When cord blood stem cells are used for allogeneic use in a fam-
ily member, the Cellular Tissue Framework imposes premarket
requirements until sufficient clinical safety and effectiveness obviate the
need for data prior to marketing.1 7 Cord Blood Stem Cells are subject
to handling and processing requirements including registration, listing,
and reporting. Additionally, the FDA intends to promulgate Good Tis-
sue Practice requirements aimed at preventing contamination and pre-
serving product integrity.11
8
B. Allogeneic Stem Cells For Non-Family Use
Minimally manipulated stem cells for unrelated allogeneic use are reg-
ulated as biologic drugs under the FDCA. Currently, the Cellular Tissue
Framework requires banks to follow donor screening, product testing,
and quarantine procedures for stem cells to be used for allogeneic use -
including familial use. Allogeneic cells must undergo testing for HIV,
CMV, HTLV, syphilis, treponemapallidum, and hepatic infection. Any
cells testing positive must be labeled "BIOHAZARD," but may be used
in limited circumstances, such as rare histocompatibility matches. If this
case arises, use may be obtained with a written informed consent and
concurrence in writing by the recipient's physician.'19
Cord blood stem cells banked for allogeneic use in non-family mem-
bers are subject to processing controls such as product chemistry, manu-
facturing, and controls ("CMCs') and premarket submissions. The
Agency will phase-in the IND and licensure submissions and intends to
eliminate the IND as soon as it is able to make a finding of safety and
effectiveness. 120 During the interim period, the FDA does not intend to
require licensure, although establishment registration and product lisitng
will be mandatory.
116. Id. at 18.
117. Id. at 21.
118. Id.
119. Id. at 26.
120. Id. at 22; see REQUEST FOR PROPOSED STANDARDS FOR UNRELATED ALLOGENEIC
PERIPHERAL AND PLACENTAI/UMBILICAL CORD BLOOD HEMATOPOIETIC STEM/PROGENI-
TOR CELL PRODUCTS; REQUEST FOR COMMENTS, 63 Fed. Reg. 2985, Jan. 20, 1998.
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VI. CONSTITUTIONAL RAMIFICATIONS OF THE PROPOSED CORD
BLOOD REGULATIONS
While the ramifications of the proposed cord blood regulations were
cause for concern, the impact of the FDA's regulatory scheme on individ-
ual constitutional rights was particularly troubling.12 I The Fifth Amend-
ment guarantees the right to property as an inherent right of all
citizens.' 22 It is a basic principle of law that the government may not
deprive a citizen of property without due process. Should the govern-
ment need to deprive an individual of property it may do so no more than
is necessary to further a legitimate government interest.1 23 Assuming ar-
guendo, that cord blood is indeed property, the FDA must provide indi-
vidual :itizens with due process, and the government interest must be
great, before the government may cause a person to relinquish the most
intrinsic property interest - life.
Parents making the decisions to store their infants' cord blood are ask-
ing banks to act as custodians of their babies' cord blood. 124 The parents
are not, however, transferring the title to their babies' cord blood; thus, it
is questionable whether cord blood banks have the right to file for an
IND on products that they do not own outright.1 21 The FDA's proposed
cord blood regulations would have effectively denied a person access to
that which is, arguably, the individual's own property. Furthermore, the
government would have lacked a sufficiently compelling 26 reason to do
so, therefore, constituting a violation of the Fifth Amendment in that the
intrusion would limit a procedure that is not intended to have an effect on
the public, but rather the individual responsible for banking the blood in
the first place. There are two issues to be resolved when analyzing the
procedural protection of property within the Fifth Amendment: whether
121. U.S. CONST. amend. V.
122. It.
123. 16A AM. JUR. Constitutional Law § 845 (1979).
124. See Cord Blood Registry Comments, supra note 98.
125. The relationship is essentially that of a bailment where there is a,
delivery of goods or personal property, by one person (bailor) to another (bailee),
in trust for the execution of a special object upon or in relation to such goods,
beneilcial either to the bailor or bailee or both, and upon a contract, express or
implied, to perform the trust and carry out such object, and thereupon either to
redeliver the goods to the bailor or otherwise dispose of the same in conformity
with the purpose of the trust.
BLACK'S ]LAW DICTIONARY 141-42 (6th ed. 1990).
126. Roe v. Wade, 410 U.S. 113, 163 (1973) (the Supreme Court held that protecting a
viable fetus in the third trimester was a compelling justification for state intrusion of per-
sonal autonomy).
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an item is property and whether the government's action deprives a per-
son of that property. 12 7
A. Organs are Personal Property
The Fifth Amendment guarantees that "[n]o person shall .. .be de-
prived of life, liberty, or property, without due process of law,' l2 but the
extent of the protection may vary. The traditional bundle of rights associ-
ated with property are possession, exclusion, 12 9 use and disposition, en-
joyment of the fruits or profits, and destruction. 130 In the United States,
the government cannot deny a person the right to the organs contained
within his or her body. The law is not clear, however, as to whether the
govenrment can deny a person the right to organs which are outside that
person's body.
Traditionally, interests related to a person have been defined as liberty
interests, and thus, enjoy Constitutional protection. 3 ' Items such as cord
blood stem cells, on the other hand, which have been removed from the
person would be divested of the personal element that denotes a liberty
interest. This would place them squarely within the definition of an item
subject to a property interest for which there are recognized constitu-
tional protections. 32
It seems elementary that a person's organs are that person's prop-
erty 133 in which she has a property interest; unfortunately, however, the
127. JOHN E. NOWAK & RONALD D. ROTUNDA, CONSTITUTIONAL LAW 513 (4th ed.
1991).
128. U.S. CONST. amend. V.
129. Arnaud v. Odom, 870 F.2d 304, 304 (5th Cir. 1989) (the court stated that "property
implies a right to exclude; you have a right to exclude from your body; therefore your body
is property").
130. Eric S. Jaffee, "She's Got Bette Davis['s] Eyes": Assessing the Nonconsensual Re-
moval of Cadaver Organs Under the Takings and Due Process Clauses, 90 COLUM. L. REV.
528, 548-49 (1990).
131. See NOWAK & ROTUNDA, supra note 127, at § 13.4.
132. See BLACK'S LAW DICTIONARY, supra note 125, at 1217 (defining personal prop-
erty as "everything that is the subject of ownership ... or any right or interest which one
has in things moveable. Generally .... goods, chattels, money, notes, bonds, stocks, and
chooses in action generally, including intangible property"). See also 63 AM. JUR. 2D Prop-
erty § 1 (1997) (stating that "as a matter of legal definition, 'property' refers not to a partic-
ular material object but to the right and interest in an object. 'Property' in a thing does
not consist merely in its ownership or possession, but also in the lawful unrestricted right of
its use, enjoyment, and disposal.")
133. It is important to draw the distinction between property interests and liberty inter-
ests. Property interests exist in objects or things while liberty interests exist in persons.
Jaffee, supra note 130, at 553.
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law is not that clear. The United States Supreme Court has stated that
the traditional determination of property is based on an entitlement13 4
rather than expectancies. 135  The National Organ Transplant Act
("NOTA")1 6 does not permit a person to sell his or her organs, yet the
sale of bodily fluids such as plasma and sperm is permitted. 37 The ability
to sell the latter items imply that they are property in which a person has
a valid property interest. The Uniform Anatomical Gift Act
("UAGA") 138 permits a person to donate all or any portion of one's body
upon death. 139 Although the UAGA permits a person to donate her or-
gans upon death, she may not arrange to sell her organs per NOTA's
prohibition. 4 °
A person has the undeniable right to use her body as she see fit, but it
is not an absolute right. 14 1 That right is subject to certain statutory and
public policy supported limitations.' 42 Technology has only recently ad-
vanced to the point where the courts have needed to address whether a
person truly has a property interest in her organs and tissues.'4 3 Histori-
134. Board of Regents v. Roth, 408 U.S. 564, 577 (1972). The Court stated that prop-
erty interests are not created by the Constitution, but that they are created and defined by
rules and understandings stemming from an independent source that secures certain bene-
fits and support claims of entitlement. Id.
135. Id.
136. National Organ Transplant Act, Title III, § 301, (codified at 42 U.S.C. § 274e
(Supp. V 1987)).
137. Fred H. Cate, Human Organ Transplantation: The Role of Law, 20 J. CoRP. L. 69,
76-77 (1995).
138. Unif. Anatomical Gift Act § 2(a), (e)(1968) (adopted in some form in every state).
See also. Cate, supra note 137, at 76-77.
139. Unif. Anatomical Gift Act ("UAGA") § 3 (1968). The following people may be
donees of anatomical gifts:
(1) any hospital, surgeon, or physician, for medical or dental education, research,
advancement of medical or dental science, therapy, or transplantation; or
(2) any accredited medical or dental school, college or university for education,
res.-arch, advancement of medical or dental science, therapy; or
(3) any bank or storage facility, for medical or dental education, research, ad-
vartcement of medical or dental science, therapy, or transplantation; or
(4) any specified individual for therapy or transplantation needed by him.
Unif. Anatomical Gift Act § 3.
140. National Organ Transplant Act, (codified as amended at 42 U.S.C. §§ 273-274e
(1988)).
141. It appears that state laws regarding prostitution and sodomy are limitations on the
rights o f an individual to utilize their body as they see fit. Additionally, the conflict regard-
ing abo:'tions, forced sterilization, and vaccination laws are areas of contention with regard
to whether a person can treat his body as he wishes. See Jaffee, supra note 130, at 544.
142. Id.
143. See William Boulier, Note, Sperm, Spleens, and Other Valuables: The Need to Rec-
ognize ,!roperty Rights in Human Body Parts, 23 HOFSTRA L. REV. 693 (1995).
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cally, society's recognition of bodily property rights has spanned the spec-
trum-from a wife as chattel to the enslavement of African-
Americans. 4 4 The common law145 and the UAGA further recognized a
quasi-property right in a cadaver that vests in the decedent's nearest rela-
tive.146 In addition, a property interest in a person's body is also recog-
nized in the common law torts of assault and battery.147 Finally, one
court has stated that "[a] person of adult years and in sound mind has the
right, in the exercise of control over his body, to determine whether or
not to submit to lawful medical treatment. 1 48
Recently, the issue of whether a person's tissues and cells constitute a
property interest has arisen in the context of claims of conversion.1 49 in
Moore v. Regents of the University of California,15 ° the California
Supreme Court held that the plaintiff did not have a claim for conversion
when his physician took excised cells from the plaintiff's body and ulti-
mately patented the cell line.'51 The court held that the patient did not
expect to retain control over his cells following their removal, and thus
found that he was not entitled to any property interest in the cells.' 52 The
court did not decide the issue of whether a person could have a property
interest in his tissues, specifically those which have been removed from
the body. The court noted that Moore did not have a property interest in
cells over which he had no intention of retaining control. 53 Neverthe-
less, the court found that Moore did have a cause of action against the
physician for breeching his fiduciary duty and for failing to obtain in-
formed consent, which together, were sufficient to provide redress for
144. Id.
145. See Jaffee, supra note 130, at 543 n.66 (citing In re Johnson, 612 P.2d 1302, 1305
(N.M. 1980)).
146. The UAGA designates those who may donate the deceased organs, thereby imply-
ing that the specified person has at least a limited property interest in the deceased's body.
Unif. Anatomical Gift Act. § 2 (1968).
147. A person has a right to have his person be free from assaults and batteries. See
generally 6A C.J.S. Assault & Battery §§ 4-12 (1975).
148. Cobbs v. Grant, 502 P.2d 1 (Cal. 1972).
149. See Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990).
150. Id.
151. Id. at 481-82. Moore was undergoing medical treatment at the Medical Center of
the University of California at Los Angeles for hairy-cell leukemia. As a result, Moore
underwent a splenectomy upon the advice of his physician. After the removal, Moore's
physician took portions of his spleen for use in research in order to initiate a cell line. The
cells line was developed and ultimately patented. Based on Moore's allegations, he as-
serted 13 causes of action each of which was demurred by the plaintiffs. Id.
152. Id. at 489.
153. Id.
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Moore's injuries.'54 The court's holding, however, left open the possibil-
ity of a future recognition of a property interest in a person's cells where
that person intends to retain control over those cells upon removal from
his body. This is precisely where parents have chosen to bank their in-
fants' cord blood.
In a case following Moore, the California Supreme Court held that a
decedent's cryogenically preserved sperm was his "property" over which
a probate court had jurisdiction to determine disposition.155 The issue in
Hecht v. Kane'56 arose when the decedent's live-in girlfriend, Deborah
Hecht, attempted to reclaim his sperm from the custodial care of the
sperm bank in which it had been deposited.' 57 Just before he took his
own life, the decedent assiduously made deposits in a sperm bank for
later use by Hecht.' 58
In both his will and suicide letter to his children, the decedent indicated
his desire that Hecht should become impregnated with his sperm and
bear his child posthumously.' 59 The court held that the decedent had a
property interest, which could appropriately be willed to Hecht.161 The
court explained its divergence from the general law of personal property
by recognizing in gametic material "an interim category that entitles
154. The court stated:
We need not, however, make an arbitrary choice between liability and nonliabil-
ity. Instead, an examination of the relevant policy considerations suggests an ap-
propriate balance: Liability based upon existing disclosure obligations, rather
thali an unprecedented extension of the conversion theory, protects patients'
rights of privacy and autonomy without necessarily hindering research.
Id. at 494.
155. Hecht v. Kane, 20 Cal. Rptr. 2d 275, 283 (Cal. Ct. App. 1993) [hereinafter Hecht I].
The Court stated that the decedent had an interest, "in the nature of ownership" at the
time of his death in the disposition of his sperm. Id. "Sperm which is stored by its provider
with the intent that it be used for artificial insemination is thus unlike other human tissue
because it is 'gametic material."' Id. (citing Davis v. Davis, 842 S.W.2d 588, 597 (Tenn.
1982)).
156. Hecht 1, 20 Cal. Rptr. 2d at 283. Petitioner Hecht sought a peremptory writ of
mandatc/prohibition to vacate an order directing the decedent's estate to destroy the
sperm in possession of the sperm bank. Id. at 276. The appellate court held that the trial
court's order constituted an abuse of discretion and set aside the order. Kane v. Hecht, 44
Cal. Rptr. 2d 578, 584 (Cal. Ct. App. 1995) [hereinafter Hecht I1].
157. Hecht 1, 20 Cal. Rptr. 2d at 278.
158. Id. at 276.
159. Id. at 277.
160. Id. at 283. Kane appealed Hecht I's vacate order in hopes that the subsequent
appeal would stay the distribution of the sperm. The second appellate court held that the
appeal would not stay the distribution of the sperm due to the risk of imminent injury or
loss ordered the delivery of sperm. Hecht 11, 44 Cal. Rptr. at 584.
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[sperm] to special respect because of [its] potential for human life."''
Analogously, the property value of cord blood stem cells lies in its poten-
tial for preserving human life. The parents who have banked their babies'
cord blood have every intention, as does a sperm donor, to retain control
over the cells, and although they assign the care of those cells to a prop-
erly qualified bank, that bank is to act only as a custodian.
Given the nature of cord blood stem cells, courts should recognize a
property interest in them, especially in light of the fact that the donor of
the autologous stem cells does not waive the right to claim them. These
cells belong to that donor and are not to be treated as mere refuse for
later use by a medical institution.
B. The Regulatory Scheme Deprives a Person of Their Property
If cord blood is indeed property, in which the donor has a legitimate
property interest, then the FDA promulgation of proposed cord blood
regulations constitutes an improper deprivation of that property. The
proposed cord blood regulations required that investigators and cord
blood banking entities file an IND.' 62 Although an IND may be permit-
ted to proceed within thirty days, this does not end the procedure.1 63 A
product that is required to proceed through the FDA regulatory mecha-
nism imposed for new drugs is likely to be delayed in the regulatory sys-
tem for up to fourteen years.164 Fourteen years is far too long for a
patient dying of a disease who could respond favorably to treatment with
cord blood stem cell transplants. 65 Additionally, those entities that had
the right to engage in cord blood cell banking would not have been able
to release an individual's cord blood sample without filing a supplement
to the original IND.'6 6 The supplemental filing would have further ex-
tended the time period during which a person could not access their
banked cord blood.' 67
161. Hecht 1, 20 Cal. Rptr. 2d at 283 (citing Davis v. Davis, 842 S.W.2d 588, 597 (Tenn.
1982)).
162. CORD BLOOD DRAr DOCUMENT, supra note 1.
163. See supra notes 21, 28, and accompanying text.
164. The Patent Term Restoration Act allows the patent life of a drug to be restored to
account for the period it was bogged down in regulatory review at the FDA with an upper
limit of 14 years. Patent Term Restoration Act, 35 U.S.C. § 156(c)(3) (1996).
165. According to a Tufts University study, the average total development phase for a
new biological product from 1980 to 1994 was 61 months. MARILYN E. GOSSE, PH. D. ET
AL., Tur's CENTER FOR THE STUDY OF DRUG DEVELOPMENT, U.S. APPROVAL Bio-
LOGICS: 1980 - 1994 (Mar. 22, 1996).
166. Investigational New Drug Application, 21 C.F.R. §§ 312.30, 312.31 (1996).
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Under these circumstances the government would not be taking the
cord blood for governmental use,' 6 8 but would be entirely denying access
by promulgating regulations so restrictive that the de facto result would
be to deny access to the donor's property. The Supreme Court has noted
that
[c&'ourts have held that the deprivation of the former owner
rather than the accretion of a right or interest to the sovereign
constitutes the taking. Government action short of acquisition
of title or occupancy has been held, if its effects are so complete
as to deprive the owner of all or most of his interest in the sub-
ject matter, to amount to a taking. 169
Such a denial of access may reasonably extend past the duration of the
donor'; life and constitute a complete taking of property.
Where the government has taken property by eliminating access, it
must provide reasons and process sufficient to justify the deprivation of
property. General principles of Due Process require the government to
afford an individual:
(1) adequate notice of the charges or basis for government ac-
tion; (2) a neutral decision-maker; (3) an opportunity to make
an oral presentation to the decision-maker; (4) an opportunity
to present evidence and witnesses to the decision-maker; (5) a
chance to confront and cross-examine witnesses or evidence to
be used against the individual; (6) the right to have an attorney
present the individual's case to the decision maker; (7) a deci-
sion based on the record with a statement of reasons for the
decision.
170
The proposed cord blood regulations did not afford individuals adequate
notice of the intent to restrict access and imposed substantive require-
ments without adherence to the notice and comment rulemaking proce-
dures.""' The proposed regulations also did not provide a mechanism by
which the FDA could choose not to apply the rules, thus rendering any
opportunity in which an individual could make an oral presentation to the
168. In order to accept this assertion, this Comment assumes that the government will
not change the status of those samples that have already been banked for autologous use
and deem them appropriate for allogeneic use. If the government were to utilize those
samples for allogeneic use in association with a government program, then there would be
a basis for saying that the government had performed a taking protected by the "Takings
Clause" of the Constitution. U.S. CONST. amend. V.
169. United States v. General Motors Corp., 323 U.S. 373, 378 (1945).
170. NOWAK & ROTUNDA, supra note 127, at 525.
171. Citizen's Petition, supra note 105, at 2.
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decision-maker moot. 172
In order to satisfy the requirements of the Due Process clause, individ-
ualized determinations are necessary. 173 The proposed cord blood regu-
lations, however, do not provide for an appeal to the decision-maker,
presumably the FDA reviewers.' 7 4 Individuals with cord blood stem cells
would not be permitted access to their tissues if a cord blood bank was
unable to satisfy the requirements imposed by FDA upon submission of
an IND. In addition, if a cord blood bank released an individual's cord
blood sample without satisfying the FDA requirements, it would be sub-
ject to the full panoply of FDA enforcement actions.175
Finally, although the FDA required that the cord blood banks submit
an IND, the cord blood banks did not have title to the samples.'7 6 There-
fore, the IND requirement was inappropriate. The banks could not ade-
quately represent the interests of the individual patients and an IND
submitted by a bank or a hearing with the bank would not have consti-
tuted an opportunity for each patient to represent themselves. Thus, as
the proposed cord blood regulations were constructed, the patients were
denied due process.
Implementing the proposed cord blood regulations, prior to consider-
ing the comments that have been submitted to the docket would run con-
trary to the final requirements that the decision be based upon the record
and include an explanation of the rationale behind it as required by the
Administrative Procedure Act. The FDA has previously implemented in-
terim rules without responding to comments, prompting one court to is-
sue a preliminary injunction.' 7 7 Nonetheless. The FDA implemented the
proposed cord blood regulations, stating that "[i]n the interim, individuals
wishing to pursue clinical investigations involving these products may
submit investigational new drug applications .. ,'78 This practice has
already been condemned by one court, and by engaging in it, the FDA
has, again, violated the individual's due process rights. 7
9
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174. Administrative Procedure Act, 5 U.S.C. § 556 (1994).
175. It is significant to note that the FDCA is a criminal statute with penalties including
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177. Biodynamics v. United States, Civ. No. JFM-95-919 (D. Md. Apr. 14, 1995).
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C. Propriety of FDA's Adoption of a Less Burdensome Alternative
That Does Not Infringe Upon the Constitutional Interests of
the Individuals While Maintaining Adequate
Safeguards for the Protection of the
Public Health
It is not appropriate to regulate cord blood stem cells as new drugs
because they constitute a product that is never manipulated or altered;
they are merely collected and stored. This type of regulation is overly
burdensome because the patient never transfers ownership of the product
- the product is merely held custodially by the cord blood stem cell cen-
ters. The center can never be in a position to file an investigational new
drug application for a substance that it does not own outright, and thus,
these circumstances render the proposed cord blood regulations inappro-
priate. Alternatively, the Cellular Tissue Framework is an appropriate
mechanism to regulate cord blood stem cells.
A simple promulgation of guidelines for entities engaging in cord blood
stem cell banking, and a recommendation that cord blood banks adhere
to industry standards, may be sufficient to protect the public health with-
out triggering the Fifth Amendment or causing an adverse impact on bur-
geoning technology.
The FDA's call for industry assistance in the development of cord
blood standard is an excellent way for the FDA to take advantage of
industry expertise. The industry has attempted to address the concerns
voiced by the FDA by establishing standards for cord blood stem cell
banking.' Cord Blood Associations have set standards with respect to
transplantation,181 cell collection,' 82 and cell processing.'83 In addition,
FDA concerns over false and misleading advertising claims and assertions
may be adequately addressed by the requirements in the Cellular Tissue
Framework or, alternatively, by the Federal Trade Commission. 84
180. FOUNDATION FOR ACCREDITATnON OF HEMATOPOIETIC CELL THERAPY, supra
note 12.
181. See id. at Part B (setting forth guidelines for program sizes, institutional review
board requirements, data management, quality management, staffing requirements, inpa-
tient unit requirements, and outpatient unit requirements).
182. See id. at Part C (setting forth guidelines for cell donor evaluation and selection,
cell collection facilities, cell collection procedures).
183. See id. at Part D (setting forth guidelines for hematopoietic progenitor cell
processing, cryopreservation, quality management, labels, storage, transportation, expira-
tions, and record).
184. Industries regulated by the FDA are usually carved out of the FTC's jurisdiction,
however, in some instances the FTC may take action if the practices constitute unfair or
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VII. CONCLUSION
Cord blood stem cell research is in its infancy and has the potential for
life-saving advancements if its growth is permitted to continue. Although
it may be appropriate and necessary for the FDA to exert some control
over cord blood stem cells, the FDA's proposed cord blood regulations
are overly burdensome and inappropriate at these early stages of devel-
opment and research. The adoption of less a burdensome scheme is ben-
eficial to both the industry and the public health.
The theory that organs and tissues are personal property over which
each person should have dispositional control is still in its formative
years. Arguments for a property interest under the Constitution are com-
pelling given the progress technology is making, and the issue will only
continue to grow if it is not resolved now. Assuming arguendo that per-
sons have a property interest in the tissues derived from a person's own
body, government interference should be limited to the minimum level
necessary to further the government's compelling state interests. The
mechanism the FDA has proposed to regulate cord blood is overly bur-
densome and does not provide the individual with the necessary due pro-
cess and, de facto, denies access to personal property. The FDA's
adoption of the Cellular Tissue Framework as a regulatory scheme is a
more fitting accomodation. It does not deprive citizens of access to cord
blood stem cells intended for autologous transplantation, yet it protects
the public health through less invasive means.
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